$707 Million is the total value of Omega Fund Management, LLC's 22 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 23.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NUVB | Sell | Nuvation Bio | $195,137,000 | -30.4% | 22,957,340 | -18.6% | 27.59% | -12.3% |
| REPL | Sell | Replimune Group | $129,088,000 | -11.0% | 4,763,380 | -2.7% | 18.25% | +12.1% |
| Imago Biosciences | $71,574,000 | +18.4% | 3,018,737 | 0.0% | 10.12% | +49.2% | ||
| MORF | Sell | Morphic Holding | $56,857,000 | -23.7% | 1,200,014 | -8.8% | 8.04% | -3.9% |
| KRON | Kronos Bio | $51,890,000 | -35.2% | 3,818,283 | 0.0% | 7.34% | -18.3% | |
| GOSS | Sell | Gossamer Bio | $35,794,000 | -14.2% | 3,164,835 | -4.7% | 5.06% | +8.1% |
| IKNA | Ikena Oncology | $28,204,000 | -0.6% | 2,249,123 | 0.0% | 3.99% | +25.3% | |
| ALPN | Alpine Immune Sciences | $28,110,000 | +29.8% | 2,029,580 | 0.0% | 3.97% | +63.6% | |
| IMUX | Immunic Inc | $17,113,000 | +8.1% | 1,788,160 | 0.0% | 2.42% | +36.3% | |
| SANA | Sana Biotechnology, Inc. | $13,061,000 | -31.3% | 843,750 | 0.0% | 1.85% | -13.4% | |
| ARQT | Arcutis Biothereapeutics | $12,938,000 | -13.2% | 623,836 | 0.0% | 1.83% | +9.4% | |
| Icosavax | $9,756,000 | -22.7% | 426,395 | 0.0% | 1.38% | -2.5% | ||
| SPRB | Spruce Biosciences | $9,638,000 | -25.8% | 2,161,022 | 0.0% | 1.36% | -6.5% | |
| New | Theseus Pharmaceuticals | $9,022,000 | – | 711,479 | +100.0% | 1.28% | – | |
| PRTK | Sell | Paratek Pharmaceuticals | $8,851,000 | -30.1% | 1,971,241 | -24.4% | 1.25% | -12.0% |
| SYRS | Syros Pharmaceuticals | $8,191,000 | -27.1% | 2,512,705 | 0.0% | 1.16% | -8.1% | |
| OMEG | Omega Alpha SPAC | $4,895,000 | +0.4% | 501,000 | 0.0% | 0.69% | +26.5% | |
| EPIX | ESSA Pharma | $4,660,000 | +77.5% | 328,196 | 0.0% | 0.66% | +123.4% | |
| Adagio Therapeutics | $4,595,000 | -82.8% | 632,855 | 0.0% | 0.65% | -78.3% | ||
| CMPI | Checkmate Pharmaceuticals | $3,832,000 | -27.7% | 1,335,050 | 0.0% | 0.54% | -8.9% | |
| JNCE | Jounce Therapeutics | $2,301,000 | +12.4% | 275,513 | 0.0% | 0.32% | +41.3% | |
| IMCR | Immunocore Holdings | $1,765,000 | -7.6% | 51,535 | 0.0% | 0.25% | +16.8% | |
| FGEN | Exit | FibroGen Inc | $0 | – | -130,646 | -100.0% | -0.13% | – |
| TRVI | Exit | Trevi Therapeutics | $0 | – | -1,263,408 | -100.0% | -0.20% | – |
| OBSV | Exit | ObsEva SA | $0 | – | -999,364 | -100.0% | -0.35% | – |
| CDTX | Exit | Cidara Therapeutics | $0 | – | -2,005,249 | -100.0% | -0.50% | – |
| AVIR | Exit | Atea Pharmaceuticals | $0 | – | -164,577 | -100.0% | -0.65% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Paratek Pharmaceuticals, Inc. | 34 | Q1 2023 | 39.1% |
| FibroGen, Inc. | 28 | Q3 2021 | 14.3% |
| Jounce Therapeutics | 25 | Q1 2023 | 11.6% |
| Pieris Pharmaceuticals | 23 | Q1 2021 | 5.2% |
| Replimune Group | 21 | Q3 2023 | 47.2% |
| Cidara Therapeutics | 20 | Q3 2021 | 5.8% |
| Morphic Holding | 18 | Q3 2023 | 22.0% |
| Immunic Inc | 18 | Q3 2023 | 9.0% |
| Dicerna Pharmaceuticals | 18 | Q1 2019 | 3.7% |
| Egalet | 17 | Q4 2018 | 19.6% |
View Omega Fund Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-14 |
| 13F-HR/A | 2021-11-15 |
View Omega Fund Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.